HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reckitt Sells Skin-Care Brand E45 To Karo In £200m Deal

Executive Summary

Karo Pharma is poised to expand its portfolio in the UK with the acquisition of leading skin-care brand E45 from Reckitt.

You may also be interested in...



Karo Pharma Adds VMS With Deal For Belgium's Sylphar

Sweden's Karo Pharma is acquiring Sylphar Group and its dietary supplement and beauty brands sold around Europe, primarily online.

Reckitt Raises Guidance Following Sharp Improvement In Cold & Flu Sales

A sharp improvement in cold and flu sales trends in the third quarter has prompted Reckitt to increase its sales guidance for the full year. However, the UK-based firm is warning that these trends remain unpredictable for the remainder of 2021.

Reckitt Launches ‘Largest Ever’ Digital Campaign For E45 In The UK

Developed by creative agency Havas, Reckitt's #MyEverydayExtremes campaign for E45 features 13 social media films showcasing the individual stories of British consumers with skin conditions.

Related Content

Topics

UsernamePublicRestriction

Register

RS152080

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel